The Revival of eConsent

The Revival of eConsent
December 15, 2022 YPrime

The clinical research industry has been reluctant to adopt electronic informed consent (eConsent) for several reasons, not least of which included having to disrupt already stressed and short-staffed work environments to implement new technology. COVID-19 proved to be an inflection point, however, for the industry to continue exploring and implementing digital technologies.

Fortunately, the eClinical technology industry has benefitted by implementing design techniques and user-centric approaches gleaned from consumer-oriented industries to overcome historic objections.

In this webinar, our experts will talk about the value of eConsent, why the industry has been hesitant to adopt it, factors that are driving the reexamination of this technology solution, and new approaches and features that may help the industry reconsider its value.

Watch the webinar to learn more.

WEBINAR

The Revival of eConsent

Michael Hughes and Ian Greenfield

RELATED CONTENT

Understanding Electronic Patient-Reported Outcomes (ePRO) in Clinical Development

Understanding Electronic Patient-Reported Outcomes (ePRO) in Clinical Development

eCOA Rescue and Rapid Deployment for a Phase 3 Respiratory Study

eCOA Rescue and Rapid Deployment for a Phase 3 Respiratory Study

Electronic Clinical Outcome Assessment (eCOA) For Clinical Studies

Electronic Clinical Outcome Assessment (eCOA) For Clinical Studies

LATEST CONTENT

How Modern Software Architecture is Revolutionizing IRT Solutions

How Modern Software Architecture is Revolutionizing IRT Solutions

eConsent for Clinical Trials

eConsent for Clinical Trials

Optimizing Strategies and Technologies for Decentralized and Hybrid Clinical Trials eBook

Optimizing Strategies and Technologies for Decentralized and Hybrid Clinical Trials eBook